Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMNITA Study of ramucirumab + docetaxel for recurrent non-small cell lung cancer with brain metastases
jRCTs071180048Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: progression-free survival. Started Oct 2017; status: completed.
02
Drugs
ramucirumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071180048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180048.